Top Tech Companies (83)
Don't see your company?
Create a company profile
DermBiont’s mission is to become the world’s leading precision dermatology company developing and commercializing targeted topical therapeutics that treat, cure, and prevent diseases. The company aims to impact the root causes of skin diseases through the development of targeted small molecule therapeutics with well-defined mechanisms of action and biotherapeutics that repair an imbalance of the microbiome. The company’s targeted topical therapeutics pipeline includes SM-020 for the treatment of seborrheic keratosis, SM-030 for the treatment of hyperpigmentation disorders of the skin, and DBI-001 & DBI-002 for the treatment of atopic dermatitis, tinea pedis, and onychomycosis.
We are a life sciences company that is building on over a decade of extensive research on the genetic mutations associated with cystic fibrosis. We are developing first-in-class small molecules that are focused on a unique target with the potential to fully normalize CFTR function for the first time for the vast majority of people living with CF.
Diagonal Therapeutics is a biotech company pioneering a new approach to discovering and developing agonist antibodies. The Company's DIAGONAL platform combines proprietary computational and experimental techniques to overcome historical challenges associated with agonist antibody drug discovery. Diagonal's emerging pipeline – discovered using the DIAGONAL platform – has the potential to deliver life-changing therapies to patients including therapies for hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension.
We are a vibrant science and technology company. Science is at the heart of everything we do. It drives the discoveries we make and the technologies we create. We make a positive difference to millions of people’s lives every day. Our constant curiosity and specialist approach drive our partnerships and bring new ideas to life. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – Merck is everywhere. We trust in the talent and passion of our curious minds; that's why we're creating an environment where they can unleash their potential and meet their individual needs. We foster a culture where everyone feels welcome. Our work is fueled by our belief in science as a force for good. We work to enhance the human experience and create more joyful and sustainable ways to live. We are here for people at every step, helping to create, improve and prolong life. We deliver personalized treatments for serious diseases and enable people to achieve their dream of becoming parents. We empower the scientific community. Our tools, services and digital platform make research simpler, more exact, and help to deliver breakthroughs more quickly. Our solutions accelerate access to health by assuring tests are accurate and the medicine we take can be trusted. We are the company behind the companies advancing digital living. Our science sits inside technologies that are changing the way we access, store, process, and display information. Our innovations are unlocking the power and potential of data to open new possibilities to transform life on Earth as we know it. We believe that scientific exploration and responsible entrepreneurship are key to technological advances that benefit us all. This is how Merck has thrived since 1668. And we will continue to push the boundaries of possibility to create opportunities for everyone. This is what drives us. This is what we work for. This is our future. We are curious minds dedicated to human progress.
Applied Pathology Systems is a Histopathology laboratory in Greater Boston that provides cutting-edge histology services and has a strong reputation for preparing, embedding, staining, and interpreting tissue sections. The laboratory is CLIA certified and led by experienced histologists working under the guidance of US board-certified pathologists. APS offers general histology, immunohistochemistry, digital imaging & analysis, pathology evaluation, and surgical pathology consultations. Human and veterinary board-certified pathologists specialize in Gastroenterology and Dermatology with years of subspeciality training.
Accent is leading the translation of RNA-modifying protein (RMP) biology into promising new therapies by combining a robust chemical biology platform with rigorous approaches to target identification and validation. Our seasoned team of drug developers is uniquely experienced to interrogate and advance small molecule therapies with far-reaching potential.
At PathAI our mission is to improve patient outcomes with AI-powered technology. PathAI’s platform promises substantial improvements to the accuracy of diagnosis and the efficacy of treatment of diseases like cancer, leveraging modern approaches in machine and deep learning.
Within the Health and Technology landscape, the firm’s expertise in Digital Health, Software and Technology, FinTech, Biotech, and Diagnostics inform the service we provide for our clients and partners leading these industries. We continue to build lasting partnerships across the financial sector, building out portfolio companies for top-tier Private Equity and Venture Capital firms.
Harvard Bioscience is a global developer, manufacturer and marketer of a broad range of specialized products, primarily apparatus and scientific instruments used to advance life science research at pharmaceutical and biotechnology companies, universities and government laboratories worldwide.
nirrin is developing sensors and analytics to enable the next generation of biological manufacturing. Using near-infrared spectroscopy we are able to attain real-time, reliable measurements of critical bioprocess parameters. We are primarily focused on applications within the biopharma industry however our technology has the potential to be used across the life sciences. Our small but passionate team is currently working on integrating novel near-infrared sensors with other data sources to provide process control for cell culture. We are looking for a developer with a strong design background to work with the engineering team on the next generation user interface for our data acquisition and analytics software.
JoVE is the world-leading producer and provider of science video solutions with the mission to improve scientific research and education. Millions of scientists, educators and students at thousands of universities, colleges, hospitals and biopharmaceutical companies worldwide use JoVE for their research, teaching and learning. Our institutional clients comprise over 1,000 universities, colleges, and biopharma companies, including such leaders as Harvard, MIT, Yale, and Stanford.
SiPhox is a high-impact startup in Burlington, MA integrating microfluidics, biochemistry and Silicon Photonics to miniaturize proteomics. Silicon Photonics is a platform technology for optics miniaturization that has revolutionized the data center industry over the last two decades. SiPhox’s photonic chips enable us to provide 100x smaller, 100x lower cost, highly scalable, multiplexed diagnostics. Founded in February 2020, SiPhox has expanded into an over 7000 sq. ft. lab & office space, raised $8.5 million (seed round, from backers such as Y-combinator and Khosla Ventures), and we are tirelessly working to scale our team and bring our product to market.
Matterworks is developing advanced AI-powered software and proprietary chemistry reagents to enable real-time, quantitative metabolomics to accelerate the research, development, and manufacturing of biologic therapeutics. Metabolomics measures all the small molecules a cell needs to function. In spite of its far-reaching potential impact across life science disciplines, adoption of metabolomics remains limited and lags behind other ‘omic techniques due to a number of inherent challenges. Matterworks is developing a novel alternative methodology that activates deep learning (DL) for analytical chemistry, to remove the constraints imposed by the requirement for human-interpretable data. Matterworks is on a mission to democratize metabolomics and catalyze its widespread adoption and integration into the life sciences. Our view is very simple: solving metabolomics will advance all of the life sciences industries.
Colossal is a breakthrough bioscience and genetic engineering company that builds radical new technologies to advance the field of genomics. Colossal creates disruptive technologies for extinct species restoration, critically endangered species protection and the repopulation of critical ecosystems that support the continuation of life on Earth. The company is the first to apply CRISPR technology for the purposes of species de-extinction, beginning with the woolly mammoth. Colossal is accepting humanity’s duty to restore Earth to a healthier state.
Eurofins Scientific is an international life sciences company, providing a unique range of analytical testing services to clients across multiple industries, to make life and the environment safer, healthier and more sustainable. From the food you eat to the medicines you rely on, Eurofins works with the biggest companies in the world to ensure the products they supply are safe, their ingredients are authentic and labelling is accurate. Eurofins is a global leader in food, environmental, pharmaceutical and cosmetic product testing and in agroscience CRO services. It is also one of the global independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, CDMO, advanced material sciences and in the support of clinical studies. In over just 30 years, Eurofins has grown from one laboratory in Nantes, France to over 61,000 staff across a network of over 1,000 independent companies in 59 countries, operating 940 laboratories. Performing over 450 million tests every year, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as providing innovative clinical diagnostic testing services, as one of the leading global emerging players in specialised clinical diagnostics testing. Eurofins is one of the fastest growing listed European companies. Since its IPO on the French stock exchange in 1997, Eurofins’ revenues have increased by 33% each year (in compound average) to reach €6.7 billion in 2021.
Matchpoint is a biotechnology company harnessing the power of covalency to discover precision covalent medicines to transform the treatment of immune diseases and other serious illnesses. The company's proprietary Advanced Covalent Exploration (ACE) platform integrates advanced chemoproteomics, machine learning and covalent chemistry library evolution. Matchpoint has an emerging pipeline of novel covalent medicines initially focused on immunology. For more information, please visit www.matchpointtx.com.
We've experienced the significant gaps in our collective ability, as a medical and research community, to access and understand disease-defining biology when it matters most. To address this, we've developed a simple blood test uncovers actionable disease-defining transcriptional biology. Our unique genome-wide platform profiles circulating chromatin and the DNA methylome to deliver resolution into the dynamic activity of individual genes and pathways in diseased tissues from just 1mL of plasma. By partnering with developers of new medicines and advancing our own diagnostic tests, we’re working towards a world where new medicine development efforts succeed more frequently, and where anyone can receive a minimally invasive diagnosis and treatment that’s precise to the biology of their disease.
We are an R&D company with exclusively licensed and patent pending technology to replenish mitochondria to fight disease, including neurodegenerative disorders such as ALS, Alzheimer’s, and Parkinson’s.
SmartLabs is accelerating the pace of scientific discovery by radically transforming the way the world builds and uses lab space. Where lab construction can take 9 to 12 months in the traditional process, we deliver personalized and effective lab workflow environments in about 4 weeks. This huge reduction in time means member teams are starting sooner and results are delivered faster. We continue to compound this time savings with our proactive operational support and ability to pivot and change lab space quickly as member science evolves and lab needs change. We love what we do - our members are shaping the future and we are proud to help them do it! We currently have locations in the MIT area of Cambridge, at Innovation Square in the Boston Seaport, in the hot new development at Boston Landing, and in South San Francisco. Visit our website to request a tour.
OpenClinica is transforming healthcare through innovative cloud technology that simplifies running clinical trials. Proven in over 10,000 studies worldwide, the OpenClinica platform is trusted by biopharmaceutical companies, CROs, AROs, and government agencies. Research organizations leverage OpenClinica to capture better clinical data faster with the highest standards for security and regulatory compliance.
